Title

Patient-specific alterations in blood plasma cfRNA profiles enable accurate classification of cancer patients and controls

Authors

Annelien Morlion (1,2), Philippe Decruyenaere (1,2,3), Kathleen Schoofs (1,2,4), Jasper Anckaert (1,2), Justine Nuytens (1,2), Eveline Vanden Eynde (1,2), Kimberly Verniers (1,2), Celine Everaert (4), Fritz Offner (3), Jo Van Dorpe (5), Olivier Thas (6,7,8), Jo Vandesompele° (1,2), Pieter Mestdagh°* (1,2)

°Both authors contributed equally to this work

*Corresponding author

(1) Department of Biomolecular Medicine, Ghent University, Ghent, Belgium

(2) OncoRNALab, Cancer Research Institute Ghent (CRIG), Ghent, Belgium

(3) Department of Hematology, Ghent University Hospital, Ghent, Belgium

(4) TOBI Lab, Center for Medical Biotechnology, VIB-UGent, Zwijnaarde, Belgium

(5) Department of Pathology, Ghent University Hospital, Ghent, Belgium

(6) Department of Applied Mathematics, Computer Science and Statistics, Ghent University, Ghent, Belgium

(7) Data Science Institute, I-BioStat, Hasselt University, Hasselt, Belgium

(8) National Institute for Applied Statistics Research Australia (NIASRA), University of Wollongong, Australia

Author contributions

Conceptualization: AM, CE, JV, PM

Data Curation: AM

Formal analysis: AM, OT

Funding acquisition: AM, JV, JVD, PM

Investigation: EV, JN, KV

Methodology: AM, JV, PM

Project administration: AM, JV, PM

Resources: FO, JV, JVD, KS, PD, PM

Software: AM, JA

Supervision: JV, PM

Validation: AM, OT

Visualization: AM

Writing – original draft: AM, JV, PM

Writing – review & editing: all authors

Abstract

Circulating nucleic acids in blood plasma form an attractive resource to study human health

and disease. Here, we applied mRNA capture sequencing of blood plasma cell-free RNA from

266 cancer patients and cancer-free controls (discovery n = 208, 25 cancer types; replication

n = 58, 3 types). We observed cancer type-specific as well as pan-cancer alterations in cell-

free transcriptomes compared to controls. Differentially abundant RNAs were heterogenous

among patients and among cohorts, hampering identification of robust cancer biomarkers.

Therefore, we developed a novel method that compares each individual cancer patient to a

reference control population to identify so-called biomarker tail genes. The number of

biomarker tail genes in a sample enables distinguishing an individual cancer patient from

controls. The potential of this novel approach was confirmed in additional cohorts of 65

plasma donors (2 lymphoma types) and 24 urine donors (bladder cancer). Together, our

findings demonstrate heterogeneity in cell-free RNA alterations among cancer patients and

propose that case-specific alterations can be exploited for classification purposes.

Introduction

Cancer is a complex disease with considerable heterogeneity, both between as well as within

cancer types. Finding robust and easily accessible biomarkers is crucial to improve patient

well-being and outcome. Such biomarkers can either assist in early detection of cancer,

enabling treatment to start at an earlier stage, or they can support diagnosis, treatment

selection or response monitoring. As an alternative for biomarkers that require invasive tissue

biopsies, liquid biopsy-based biomarkers such as circulating nucleic acids have emerged as a

promising tool for cancer diagnosis and monitoring.

To date, most studies on circulating nucleic acids in cancer patients have focused on circulating tumor DNA (ctDNA). The amount of tumor DNA in circulation is highly dependent on the tumor type and burden[1], suggesting that ctDNA can be less informative for certain cancer types or early-stage cancers. Cell-free RNA (cfRNA) may complement ctDNA by reflecting dynamic changes in gene expression during cancer development and progression, or upon treatment, in both healthy and diseased cells. A recent study showed that different cell types contribute RNA to the healthy cell-free plasma transcriptome, and that cfRNA allows monitoring of cell-type-specific changes in diseases, such as non-alcoholic fatty liver and Alzheimer's disease[2]. The potential of cfRNA as prognostic biomarker has also been demonstrated for pre-eclampsia and organ damage in pregnancy[3]. Some studies have also shown potential of using cfRNA biomarkers in certain cancer types[4–6]. Larson et al.[4] specifically looked at genes that are "dark" (no or few detected transcripts) in plasma from healthy controls but abundant in plasma from lung and/or breast cancer patients and found indications of tissue-of-origin signal. Chen et al.[5] reported potential of combining human and microbe-derived plasma cfRNA for distinguishing healthy donor and cancer plasma samples (colorectum, stomach, liver, lung, and esophageal cancer) based on profiles of RNAs showing group-level differences. Roskams-Hieter et al.[6] showed plasma cfRNA classification potential for liver cancer and multiple myeloma patient samples compared to non-cancer controls, with a higher accuracy using learning vector quantization feature selection compared to group-level differential abundance. The authors, however, indicated that liver and bone marrow are major contributors to the plasma transcriptome which may result in more cancer signal.

Here, we further examined the impact of different cancer types on plasma cfRNA profiles in different cohorts (Table 1). We first quantified cell-free mRNAs in different cohorts of blood plasma from cancer patients with locally advanced or metastatic tumors and cancer-free donors to uncover tumor or tissue-of-origin mRNA signatures with diagnostic potential. Results revealed substantial heterogeneity in cell-free mRNA abundance among cohorts, questioning the biomarker potential of cell-free mRNA signatures. However, patient-specific alterations, reflected by the number of cell-free mRNAs with differential abundance in a patient sample compared to a cancer-free control population, enabled to accurately distinguish cancer patients from healthy individuals.

 Table 1: Cohort overview. Name, number of donors (one sample per donor), biofluid type, library preparation

method and application of the cohort in this study. (*) eight control donors overlap with pan-cancer cohort, data

from these eight donors was only used for discovery of the tail gene concept, not for replication of pan-cancer

analyses (see Methods).

cohort name	cancer patients (cancer types)	controls	biofluid	library preparation	purpose
pan-cancer cohort	200 (25)	8	plasma	mRNA capture (Illumina DNA Prep with Enrichment)	discovery
three-cancer cohort	36 (3)	30*	plasma	mRNA capture (Illumina DNA Prep with Enrichment)	replication pan-cancer analyses & discovery tail gene concept
lymphoma cohort	43 (2)	22	plasma	total RNA (SMARTer Stranded Total RNA-Seq Kit v3 - Pico Input Mammalian)	tail gene concept in independent plasma cohort
bladder cancer cohort	12 (1)	12	urine	mRNA capture (TruSeq RNA Exome)	tail gene concept in independent urine cohort

Results

A diverse repertoire of cell-free mRNAs in plasma

To characterize the blood plasma cell-free mRNA transcriptome, we collected blood plasma from a pan-cancer discovery cohort consisting of 208 individuals covering 25 different cancer types and aged-matched healthy controls (Fig.1a, Supplementary Table 1). MRNA capture sequencing of the pan-cancer plasma cohort resulted in 3 to 56M paired-end reads per sample (median 16M) after quality filtering with no significant differences among groups (Kruskal-Wallis test p > 0.05) (Extended Data Fig.1a). On average 84% (95% CI [82.59, 84.66]) of uniquely mapped reads were assigned to protein coding genes and most other reads originated from mitochondrially encoded ribosomal RNAs (Extended Data Fig.1b). Per sample, between 7439 and 13,039 unique mRNAs (median 10,932) were detected with at least 10 counts – we use the term mRNA to refer to all mRNA reads mapping to the same gene (Fig.1b). All plasma samples had 5263 mRNAs in common and 9908 mRNAs were found in at least 75% of the samples. Of note, we detected more mRNAs in plasma from acute myeloid leukemia (AML) patients compared to plasma from controls and from patients with solid cancers (Kruskal-Wallis p = 6.6E-4, effect size = 0.163, *post hoc* two-sided Wilcoxon rank-sum q < 0.05 for AML vs controls and 16 out of 24 solid cancer types). Although some AML samples were sequenced deeper, sequencing depth alone did not explain the higher number of detected mRNAs (Extended Data Fig.1c). We next determined the mRNA concentration using synthetic

RNA spikes that were added to each lysed plasma sample (Fig.1c). MRNA concentrations

ranged from 0.003 to 8.302 ng/ml with an average concentration of 0.486 ng/ml. Despite the

higher number of detected mRNAs, the mRNA-concentration in AML plasma was not

significantly higher than controls or other cancer types. Moreover, though the largest median

mRNA concentration (READ, 0.648 ng/ml) was more than 10 times higher than the smallest

median (ANA, 0.063 ng/ml), no significant concentration differences were found among the

groups (Kruskal-Wallis test p = 0.0275, effect size = 0.087, with all *post hoc* two-sided

Wilcoxon rank-sum q > 0.05). Besides the small sample sizes, this may be related to the

considerable cfRNA concentration variability between patients, which is also reported at

cfDNA level[7].

We then searched for evidence of tumor-derived cfRNA by investigating known cancer fusion

transcripts in individual plasma samples. In every cancer plasma sample, we only considered

fusion transcripts that had been documented in tumor tissue of that same cancer type. Such

fusion transcripts were only identified in plasma samples of AML patients. The *PML::RARA*

fusion transcript[8] was found in two AML plasma samples with several reads supporting the

fusion (7 to 19 spanning pairs and 6 to 9 unique spanning reads). The reciprocal *RARA::PML*

fusion was found in one of both AML plasma samples (19 pairs and 17 unique reads). In

plasma samples of solid cancer types, we only detected fusion transcripts that had not been

reported in the tumor tissue of these cancer types (Supplementary Table 2). Of note, these

fusion transcripts had fewer supporting reads (1 to 2 pairs and 2 to 5 unique reads) than the

PML::RARA/RARA::PML fusions in AML and may thus represent false positives. Moreover,

other fusions with few supporting reads were also identified in healthy control plasma

samples. While the two AML samples with the *PML::RARA* fusion transcripts were sequenced

deeper than other samples, the fusions were still detected when downsampling to the

median number of reads of the pan-cancer cohort. These analyses confirm the presence of

tumor cell-derived cfRNA in plasma samples from AML patients.

Fig.1: Pan-cancer plasma cohort overview, mRNA content and sample clustering. *a, Primary sites of the 25 cancer types in the pan-cancer cohort. Primary sites are indicated with colored dots and corresponding cancer types are listed (top to bottom) with the (sub)type abbreviations between brackets. Details can be found in Supplementary Table 1. **b**, Number of plasma mRNAs, detected with at least 10 counts, across cancer types and healthy controls. Groups ordered according to median. **c**, Variability in plasma mRNA concentration across cancer types and healthy controls. Groups ordered according to median. **b** and **c**, Boxplots show lower quartile (Q1), median, and upper quartile (Q3). Whiskers extend from the lower and upper quartile to the smallest and largest value, respectively, within at most 1.5*interquartile range (Q3-Q1) from that quartile. More extreme points are plotted as individual dots. **d**, Principal component analysis using the 500 most variable mRNAs in the pan-cancer cohort (with variance stabilizing transformation DESeq2). Yellow squares: control samples; red triangles: acute myeloid leukemia samples; blue dots: non-leukemia cancer samples. **e** and **f**, Principal component analysis using the 500 most variable mRNAs in controls and anaplastic astrocytoma (ANA) or prostate cancer (PRAD) patients, respectively. Replicate numbers are indicated in the plot. PC: principal component.*

Differential mRNA abundance in cancer patients' plasma compared to controls

Principal component analysis revealed a clear separation between AML and other plasma samples for six out of eight AML patients, with and without downsampling AML sample reads to the median of the cohort (Fig.1d & Extended Data Fig.1d). Control samples mostly clustered in between samples of solid tumors. Analysis of individual solid tumor types revealed that most patient samples could be separated from controls in the first two principal components (Fig.1e and f, Extended Data Fig.2), suggesting that plasma cfRNA profiles of cancer patients differ from that of controls.

Differentially abundant mRNAs were identified in every cancer-control comparison, with numbers varying from 10 to 2583 (median 128) for higher abundant mRNAs and from 89 to 2727 (median 221) for lower abundant mRNAs in cancer compared to control (Fig.2a). Most differentially abundant mRNAs were found in AML (5310 mRNAs, or 5347 mRNAs when downsampling reads to the median reads in cohort). Uterine cancer (UCEC) and sarcoma (SARC) completed the top 3 with 1154 and 763 mRNAs, respectively. Head and neck (HNC), rectal (READ) and breast cancer (BRCA) had the lowest number of differentially abundant mRNAs (127, 136, and 145 respectively).

In total, 6758 unique mRNAs were differentially abundant in one or more cancer-control comparisons (b) and the median absolute fold change was 3.1. One quarter of differentially abundant mRNAs had an absolute fold change of at least 4.6. Hierarchical clustering based on differential mRNA abundance mostly separated cancer and control samples but also revealed variability in gene abundance within groups (Fig.2b, Extended Data Fig.3).

4442 mRNAs (66%) were differentially abundant in one cancer type only (Fig.2c), and most (3680 mRNAs) were identified in AML. While many mRNAs were differentially abundant in plasma of only one or a few cancer types, 26 differentially abundant mRNAs were recurrent in 23 out of 25 cancer-control comparisons (Fig.2c). These mRNAs were all lower abundant in cancer compared to controls and showed enrichment for inflammatory and immune response pathways (Supplementary Table 3).

Fig.2: Differentially abundant mRNAs in cancer versus control. *a, Differentially abundant mRNAs in plasma from cancer patients versus controls. Cancer types ordered based on total number of differentially abundant mRNAs ($q < 0.05$ and $|log_2 fold change| > 1$). b, Volcano plot and heatmap of differentially abundant mRNAs in anaplastic astrocytoma vs controls (other cancer-control comparisons in Extended Data Fig.3). Volcano plots have a horizontal line at $q = 0.05$ and vertical lines at log_2 fold change of -1 and 1, resp. Higher (red): higher abundant in cancer compared to control samples ($q < 0.05$ and log_2 fold change > 1); lower (blue): lower abundant in cancer compared to control samples ($q < 0.05$ and log_2 fold change < -1). Heatmaps show relative abundance of differentially abundant mRNAs (columns) in individual plasma samples (rows). Heatmap colors represent log2(normalized counts+1) followed by z-score transformation per gene (z). Clustering of genes and samples based on Pearson correlation. c, Recurrence of differentially abundant mRNAs (shown in a) across cancer types.*

Enrichment of pathways and cell types in cancer patients' plasma

To explore the pathways, cell types and tissues underlying the differentially abundant mRNAs in cancer plasma, we first applied gene set enrichment analyses using hallmark[9], Kyoto Encyclopedia of Genes and Genomes (KEGG)[10], and custom tissue- and cell type gene sets (Fig.3a, Extended Data Fig.4a & b). We observed a negative enrichment of various immune-

related signals (interleukin signaling, interferon gamma and inflammatory response, and
neutrophils) across all cancer types except UCEC, with q < 0.05 in at least 21 out of 25 cancer
types. We also found a negative enrichment of the KEGG ribosome gene set in all solid cancer
types (q < 0.05 in 19 out of 24 types) (Extended Data Fig.4b). These results are in line with a
previous study by Chen et al.[5] on plasma cfRNA profiles of five early-stage solid cancer types.
Other negatively enriched gene sets with q < 0.05 in at least half of the cancer types in our
cohort were blood related (Fig.3a, Extended Data Fig.4a & b). Conversely, 'extracellular matrix
receptor' and 'focal adhesion' gene sets were significantly positively enriched in at least half
of the cancer types (Extended Data Fig.4b), confirming results by Chen et al. Other positively
enriched gene sets included those related to KRAS signaling, epithelial-mesenchymal
transition, myogenesis, adipose tissue, brain function, and hematopoietic stem cells. (Fig.3a,
Extended Data Fig.4a).

Cancer type-specific enrichment of cfRNA reflecting the primary tumor site was only observed
for liver cancer patients. 'Liver tissue', 'liver cancer tissue', and 'hepatocyte' gene sets were
all positively enriched in liver cancer patients' plasma (q < 0.05, Fig.3b) and not in plasma from
any other cancer type. A 'bronchial epithelial cells' gene set was significantly enriched in lung
adenocarcinoma and lung squamous cell carcinoma (LUAD q = 0.027; LUSC q = 0.026), but this
enrichment was also found in four other cancer types (ANA, CESC, CHOL, and UCEC).

We then applied computational deconvolution to enumerate the cell type fractions
contributing to plasma cfRNA profiles (Supplementary Table 4). Platelets,
erythrocytes/erythrocyte progenitors, monocytes, macrophages, and B-cells formed the top-
5 of most abundant cell types that contributed to plasma cfRNA of both controls and patients
with solid tumors (Fig.3c). Except for macrophages, these cell types were also reported as the
most abundant cell types in a previous study on healthy donor plasma[2]. Plasma from AML
patients showed a very different composition. Several cell type contributions - including
hematopoietic stem cells, myeloid progenitor cells, and monocytes - were increased or even
exclusively present in AML plasma samples, in line with the blood cell counts typically
observed in these patients[11]. Myeloid progenitor cells, normally not present in peripheral
blood, were an abundant contributor in the AML plasma samples (mean 10.7%, or 8.5% when
downsampling AML reads to the cohort median), with almost no signal in other plasma
samples (mean 0.1%) (Extended Data Fig.4c). Moreover, the platelet fraction in AML plasma
was significantly lower compared to other groups (two-sided Wilcoxon rank sum p = 3.8E-5,

effect size = 0.289) with on average 18.3% in AML compared to 62.3% in other samples,

reflecting the reduced thrombocyte counts commonly found in leukemia patients[11].

In plasma from patients with solid tumors, the platelet fraction was significantly higher

compared to controls (Extended Data Fig.4c, two-sided Wilcoxon rank-sum p = 2.3E-2, effect

size = 0.163), which is in line with the prognostic value of platelet counts and the frequent

occurrence of thrombocytosis in solid tumor patients[12,13]. For neutrophils,

erythrocyte/erythroid progenitor cells, thymocytes, and T-cells, the fraction was significantly

lower in cancer patients' plasma compared to controls (two-sided Wilcoxon rank-sum p =

1.8E-2 (effect size = 0.169), p = 1.4E-2 (effect size=0.176), p = 1.8E-2 (effect size=0.164), p =

4.3E-4 (effect size = 0.252), respectively).

Independent cohort confirms systemic signal and cfRNA heterogeneity

To verify our findings, we processed an independent (three-cancer) cohort of plasma samples

which, after removing samples with low read depth, included samples from 20 cancer-free

control donors and 35 cancer patients with one of three different solid cancer types: prostate

(PRAD, n = 12), ovarian (OV, n = 11), and uterine (UCEC, n = 12) cancer. 7 to 61M paired-end

reads were obtained per sample (median 28M) with no significant difference in sequencing

depth among groups (Kruskal-Wallis p = 0.7858) (Extended Data Fig.5a). In line with the pan-

cancer cohort, we detected between 8642 and 11,944 mRNAs per sample (Extended Data

Fig.5b), with 6194 mRNAs shared across all plasma samples of this three-cancer cohort. MRNA

concentrations ranged from 0.007 to 0.414 ng/ml (Extended Data Fig.5c).

Most cancer samples could be separated from controls in the first principal component,

especially for prostate and ovarian cancer (Fig.4a). Based on differential abundance analyses

between cancer and control samples, we found the highest number of differentially abundant

mRNAs in OV (995 higher abundant, 1644 lower abundant), followed by PRAD (848 higher

abundant, 1043 lower abundant) (Fig.4b). The lowest number of differentially abundant

mRNAs was found for UCEC (243 higher abundant, 349 lower abundant) even though this

cancer type had the most differentially abundant mRNAs in the pan-cancer cohort.

Hierarchical clustering based on differential mRNA abundance in this three-cancer cohort

mostly separated cancer and control samples but again revealed variability in mRNA

abundance within groups (Extended Data Fig.5d).

189 and 299 mRNAs were significantly higher and lower abundant, respectively, in plasma

from all three cancer types compared to controls (Fig.4b). The lower abundant mRNAs

included all 26 mRNAs that were identified as lower abundant in most cancers in the pan-

cancer cohort. There was a significant, although limited, overlap in differentially abundant

mRNAs between the three-cancer and the pan-cancer cohort for each of the three cancer

types (Fisher's exact test on lower abundant mRNAs: OV p = 8.4E-118 (odds ratio = 30.0),

PRAD p = 1.1E-155 (odds ratio = 59.3), UCEC p = 7.6E-13 (odds ratio = 4.2); on higher abundant

mRNAs: OV p = 4.0E-4 (odds ratio = 4.6), PRAD p = 2.9E-52 (odds ratio = 12.2), UCEC p = 2.2E-

5 (odds ratio = 3.3); Jaccard index [0.009-0.143]) (Fig.4c and Extended Data Fig.6a). Despite

the uniform collection and processing of samples from patients with the same cancer type,

the low Jaccard indices indicate high heterogeneity between the two cohorts, as illustrated

with probabilistic modelling for varying cohort sizes (Supplementary Analysis 1). Respectively

38%, 49%, and 95% of the differentially abundant mRNAs in OV, PRAD, and UCEC in the pan-

cancer cohort could not be confirmed in the three-cancer cohort. Notably, mRNAs with lower

abundance showed a higher overlap between both cohorts than mRNAs with higher

abundance.

In line with the pan-cancer cohort, there was no enrichment of cancer type-specific gene sets

reflecting tumor tissue of origin in the OV, PRAD and UCEC samples in the three-cancer

cohort. However, enriched gene sets shared among at least half of the cancer types in the

pan-cancer cohort were confirmed in the three-cancer cohort, except for adipose tissue

(Fig.4d, Extended Data Fig.6b and c).

Cell type deconvolution confirmed platelets, erythrocyte/erythroid progenitor cells,

monocytes and B-cells among the top-5 cell types contributing cfRNA to plasma (Fig.4e,

Supplementary Table 4), with neutrophils being ranked as the fourth most abundant cell type.

The higher platelet fraction in cancer patient plasma was even more pronounced in the three-

cancer cohort (two-sided Wilcoxon rank-sum cancer versus control p = 5.8E-9, effect size =

0.679), especially for ovarian and prostate cancer (Extended Data Fig.6d). Neutrophils,

erythrocyte/erythroid progenitor cells, thymocytes and T-cells again had a lower plasma

fraction in cancer patients compared to controls (two-sided Wilcoxon rank-sum p=4.4E-6

(effect size = 0.556), p = 3.2E-7 (effect size = 0.610), p = 6.4E-5 (effect size = 0.419), p = 4.1E-

2 (effect size = 0.261), respectively).

Taken together, the limited overlap of differentially abundant mRNAs between the pan-

cancer and three-cancer cohort highlights plasma transcriptome variability, yet enrichment

and cell type contribution analyses confirm the systemic cfRNA changes in plasma from

cancer patients.

Fig.4: Three-cancer cohort confirms findings from pan-cancer cohort and reveals significant, yet limited,
304
overlap in differentially abundant mRNAs. a, Principal component analysis on top 500 most variable mRNAs
305
shows distinct clustering of most cancer and control samples (variance stabilizing transformation DESeq2). b,
306
Overlap between differentially abundant mRNAs detected in individual cancer-control comparisons. Circles are
307
proportional to the number of genes. c, Overlap between differentially abundant genes in prostate cancer versus
308
control for the pan-cancer and three-cancer cohort. Fisher's exact test: p = 2.9E-52, odds ratio = 12.2, Jaccard
309
index = 0.083 for higher abundant mRNAs in cancer versus control (higher); p = 1.1E-155, odds ratio = 59.3,
310
Jaccard index = 0.143 for lower abundant mRNAs (lower). Circles are proportional to the number of genes. d,
311
Gene set enrichment analysis results for custom tissue and cell type sets. Only pathways of Fig.3a shown. Gene
312
sets with q < 0.05 colored according to normalized enrichment scores (NES). e, Average fraction of the five most
313

cfRNA tail genes distinguish cancer samples from controls

Apart from liver cancer and AML, our analyses did not reveal evidence for a tumor or tissue

of origin signal among mRNAs that were more abundant in cancer patient versus control

plasma. Moreover, higher abundant mRNAs were less recurrent across cancer types and

showed lower reproducibility between cohorts compared to mRNAs with lower abundance

in cancer versus control plasma. Our analyses suggest that the latter represent a systemic

immune response rather than a tumor derived signal. Based on these observations, we

hypothesized that (tumor derived) cfRNA signals may be heterogeneous among patients, and

that classic differential mRNA and pathway abundance analysis between groups may not

reveal such non-uniform signals. We therefore decided to investigate cfRNA profiles in

individual cancer patients using samples from the three-cancer cohort.

To capture aberrations in the cfRNA profile of an individual cancer patient, we compared the

mRNA abundance of a cancer plasma sample to the mRNA abundance distribution in the

entire control group, that served as a reference. More specifically, a z-score was calculated

for each mRNA based on the mean and standard deviation of the $\log_2$ normalized count

distribution in the control group. Abundant mRNAs with an absolute z-score of at least 3 were

defined as "tail genes" for that patient, referring to their position in one of the tails of the

control z-score distribution (Fig.5a).

We searched for tail genes in each cancer patient from the three-cancer cohort (where we

could take advantage of a large control group) and in each control sample, always using all

other control samples as reference (Extended Data Fig.7a & b). We identified a total of 3311

unique tail genes in this cohort and observed a significantly higher number of tail genes in

plasma samples from cancer patients compared to controls (Kruskal-Wallis p = 0.0012, effect

size = 0.222, Fig.5b). 74% of the tail genes were not identified as differentially abundant in

cancer samples versus controls (Fig.5c). Moreover, for 40.0% of cancer sample tail genes that

were differentially abundant between cancer and controls, the direction (i.e. positive or

negative z-score) in at least one cancer sample was opposite to the direction reported by the

differential abundance analysis, further highlighting the heterogeneity among patients.

Notably, the recurrence of tail genes was much higher in cancer samples than controls; 98%

of the control tail genes were identified in only one control sample while 47% of cancer tail

genes were identified in more than one cancer sample (Fig.5d).

To determine the significance of the observed results, we randomly swapped sample labels

prior to tail gene identification and repeated this procedure 20 times. Doing so, we did not

observe a significant difference in number of tail genes between the newly labeled cancer

samples and controls in any of the repeats (all Kruskal-Wallis p≥0.05), confirming that an

increased number of tail genes is specifically associated with cancer samples.

Tail genes detected in one cancer type showed significant overlap with tail genes detected in

another cancer type (Fisher's exact tests p≤5.4E-168, odds ratio: [11.1-15.2]), yet limited

similarity (Jaccard index: [0.197-0.348]) (Fig.5e). The 1182 unique control tail genes also

showed significant overlap with any of the cancer tail gene subsets (pairwise Fisher exact tests

p: [5.9E-15 - 8.5E-32], odds ratio: [2.1-2.5]) with less similarity (Jaccard index: [0.074-0.119]).

63% of control tail genes were not identified as tail gene in any of the cancer samples.

Seven Cancer Gene Census oncogenes were identified as tail genes (z > 3) in at least one

sample, which is significantly more than expected by chance (Fisher's exact p = 0.019, odds

ratio = 3.13). While most oncogenes were only identified as tail gene in a single sample, *KAT6A*

was found in seven cancer samples (4 OV, 2 PRAD, and 1 UCEC) but also in one control sample.

Overrepresentation analyses (Extended Data Fig.8, Supplementary Table 5) demonstrated

that tail genes that are higher abundant in at least one cancer sample (z > 3) were involved

in different processes including platelet activation and signaling, actin binding and dynamics,

and extracellular matrix. Tail genes that are lower abundant in at least one cancer sample (z

< -3) were mainly related to mRNA splicing and translation. Significantly enriched processes

in the cancer tail gene sets were not enriched in the control tail gene set, and processes

enriched in the lower abundant (cancer) tail genes showed higher recurrence across the three

cancer types compared to those enriched in the higher abundant tail genes.

Given the higher number of tail genes in cancer versus controls, we further assessed the

binary (cancer/control) classification potential of the number of tail genes per sample. We

used a 10x 5-fold cross-validation in which we first selected a subset of tail genes, further

coined biomarker tail genes (BTG), that were significantly associated to either the cancer or

control state using Fisher's exact tests on the training set (see Methods). This resulted in sets

of 43 to 549 BTG. None of these BTG were recurrent tail genes in the control samples, and for

BTG identified in at least half of the cross-validation folds, 43% were not identified as

differentially abundant in any cancer type compared to controls (Extended Data Fig.9).

Applying the same biomarker tail gene selection strategy to 10 iterations of randomly

swapping sample labels resulted in considerably fewer or no biomarker tail genes at all:

between 0 and 6 BTG (median: 0) instead of 43 to 549.

When selecting biomarker tail genes in a specific cancer group versus controls, we obtained

17 to 271 biomarker tail genes for OV, 6 to 82 for PRAD, and 2 to 16 for UCEC. We then built

a classifier for discriminating cancer and control samples based on the number of tail genes

belonging to the BTG set in a particular sample. Using 10x 5-fold cross-validation, we obtained

a high binary classification for ovarian or prostate cancer samples and controls (mean AUC =

0.901 and 0.964, resp.), yet a lower classification performance for uterine cancer samples and

controls (mean AUC = 0.586) (Fig.5f). Classification performance was still high when

combining cancer samples for BTG identification (mean AUC = 0.879), with a better

performance for male donors compared to female donors (Supplementary Table 6).

The consensus set of BTG present in at least half of the 10x 5-fold cross-validations, consisted

of 38 BTG for OV, 18 for PRAD, 3 for UCEC, and 63 for all three cancer types combined. OV

and UCEC consensus BTG sets do not overlap. The overlap for OV and PRAD as well as for

PRAD and UCEC is significant but the similarity is limited (Fisher's exact $p \leq 1.6E-2$; odds ratio:

18.5 and 94.7; Jaccard index: 0.06 and 0.05) (Fig.5h).

The difference in number of consensus biomarker tail genes between cancer and control

samples per biomarker tail gene subset was more pronounced than based on all tail genes

(two-sided Wilcoxon rank-sum: for OV $p = 7.3E-8$ and effect size = 0.876; for PRAD $p = 1.0E-8$

and effect size = 0.920; for UCEC $p = 9.4E-5$ and effect size = 0.629; for all cancers combined

$p = 1.8E-10$ and effect size = 0.810) (Fig.5b and g).

Together, these analyses suggest that individual cancer samples can be distinguished from

controls based on the number of biomarker tail genes in their plasma cfRNA profiles.

Fig.5: Higher number of (biomarker) tail genes in cancer patient plasma samples compared to controls. *a, Tail gene identification workflow. A gene in a particular sample for which the abundance deviates more than 3 standard deviations from the reference group abundance distribution is a tail gene for that sample. The number of tail genes is used as a metric to determine cancer/control status. **b,** Boxplot of the number of tail genes per group, with grey dots representing individual sample counts. Kruskal-Wallis p = 0.001, effect size = 0.222. Two-sided Wilcoxon rank-sum q-values for specific cancer versus control comparisons indicated in the plot. **c,** Z-score distribution of tail genes in the different samples, all 3312 genes that fulfilled tail gene criteria in at least one of the samples are shown. For visualization purposes, z-scores above 5 or below -5 were reduced to 5 and -5, respectively. Genes (rows) clustered based on Euclidean distance. **d,** Number of tail genes shared by a certain fraction of samples of the same type. Number of samples indicated between brackets. **e,** Overlap between tail*

*genes detected in the different cancer types. **f**, mean ROC curves of 10x 5-fold cross-validation for binary*
cancer/control classification in test sets based on the number of biomarker tail genes for control and ovarian
cancer samples (OV), prostate cancer samples (PRAD), uterine cancer samples (UCEC), or all cancer samples (all)
*using the respective biomarker tail gene sets in the training sets. **g**, Boxplot of number of 50% consensus*
biomarker tail genes per subset in control (CONTROL) versus the respective cancer samples. Total number of
biomarker tail genes considered for each comparison: 63 for all cancer (n = 35) versus control, 38 for OV versus
control, 18 for PRAD versus control, 3 for UCEC versus control. Grey dots represent individual sample counts.
*Two-sided Wilcoxon rank-sum p-values indicated in plot. **h**, Overlap of cancer type-specific biomarker tail genes.*
Boxplots show lower quartile (Q1), median, and upper quartile (Q3). Whiskers extend from the lower and upper
quartile to the smallest and largest value, respectively, within at most 1.5*interquartile range (Q3-Q1) from that
quartile. More extreme points are plotted as individual black dots. 62 plasma samples considered in total from
27 cancer-free controls (CONTROL), 11 ovarian cancer (OV), 12 prostate cancer (PRAD), and 12 uterine cancer
patients (UCEC)).

To independently assess the classification potential of the number of biomarker tail genes,
we generated additional plasma cfRNA profiles (lymphoma cohort), including plasma samples
from 22 cancer-free control donors and 43 lymphoma patients, more specifically 30 diffuse
large B-cell lymphoma (DLBCL) and 13 primary mediastinal large B-cell lymphoma (PMBCL)
patients. We identified 5374 unique tail genes, again with more tail genes in cancer samples
compared to controls (Kruskal-Wallis p = 2.9E-5, effect size = 0.305, Extended Data Fig.10a).
All control tail genes were identified in only one control sample while 45.9% of DLBCL and
44.2% of PMBCL tail genes were identified in more than one DLBCL and PMBCL sample,
respectively (Extended Data Fig.10b). When swapping sample labels (20 repeats) prior to tail
gene identification, no significant differences in the number of tail genes between cancer and
control samples were observed in any of the repeats (Kruskal-Wallis p≥0.05).
Among the tail genes, 64 to 326 lymphoma BTG, 21 to 220 DLBCL BTG, and 87 to 677 PMBCL
BTG were identified using Fisher's exact tests in 10x 5-fold cross-validation. The binary
classifiers (cancer/control) based on biomarker tail genes in the training sets resulted in a
mean AUC of 0.765 for DLBCL, 0.951 for PMBCL, and 0.866 for all lymphoma in the test sets
(Fig.6a). Again, we observed a better performance for samples from male compared to female
donors (Supplementary Table 6). When looking at biomarker tail genes that were identified
in at least half of the iterations, we found 60 consensus BTG for DLBCL, 371 for PMBCL, and
151 for lymphoma. The number of tail genes belonging to these sets was again significantly
higher in cancer compared to control samples (Fig.6b). 59% of these consensus BTG were not

differentially abundant in any lymphoma subtype versus controls. Notably, early-stage
lymphoma patients also displayed an increased number of biomarker tail genes (Fig.6c) and
the number of detected BTG per sample was not significantly linked to cancer staging
(Jonckheere-Terpstra p = 0.9374 for DLBCL and p = 0.8949 for PMBCL).

To test if our cancer-control classification strategy based on biomarker tail genes is also
applicable to other biofluids, we applied it to a cohort of urine cfRNA profiles (bladder cancer
cohort)[14]. This cohort included urine samples of 12 bladder cancer patients (BLCA) and 12
cancer-free control donors. We identified 1152 tail genes in total and again only observed
recurrence in cancer samples (Extended Data Fig.10d). 10x 5-fold cross-validation yielded 2
to 93 biomarker tail genes and the binary classifiers based on these biomarker tail gene sets
resulted in a mean AUC of 0.829 in the test sets (Fig.6d). 6 biomarker tail genes were present
in at least half of the iterations and the number of tail genes belonging to this 50% consensus
set was significantly higher in bladder cancer versus control samples (Fig.6e). In line with the
other datasets, sample label swapping prior to tail gene identification did not result in
significant differences in the number of tail genes between the newly labeled cancer samples
and controls.

Taken together, our results confirm that the number of biomarker tail genes in blood plasma
cfRNA enables accurate classification of cancer patients from controls and suggest that the
concept may also be applicable to cfRNA profiles from other biofluids.

Fig.6: Number of biomarker tail genes is significantly higher in cancer versus control samples in an independent blood plasma and urine cohort. *a-c, lymphoma cohort: plasma samples from 22 control, 30 diffuse large B-cell lymphoma (DLBCL), and 13 primary mediastinal large B-cell lymphoma (PMBCL) patients. **d-e**, bladder cancer cohort: urine samples from 12 control (CONTROL) and 12 bladder cancer (BLCA) patients. **a**, mean ROC curve of 10x 5-fold cross-validation for binary cancer/control classification based on the number of biomarker tail genes for control and DLBCL, or control and PMBCL using the respective biomarker tail gene sets. **b**, boxplot of number of 50% consensus biomarker tail genes in control versus the respective cancer samples. Total number of biomarker tail genes considered for each comparison: 60 for DLBCL versus control, 371 for PMBCL versus control, 151 for both lymphoma types versus control. Grey dots represent individual sample counts. **c**, number of biomarker tail genes of panel b visualized per cancer stage**d**, mean ROC curve of 10x 5-fold cross-validation for binary cancer/control classification based on the number of biomarker tail genes. **e**, boxplot of number of 50% consensus biomarker tail genes in control versus cancer samples. 6 biomarker tail genes considered in total. Wilcoxon rank-sum p-values indicated in the plots. Boxplots: lower quartile, median, upper quartile, whiskers of 1.5*interquartile range; more extreme points are indicated by black dots.*

Discussion

In this study, we explored cancer-induced changes in blood plasma cfRNA profiles and investigated if these changes could be exploited for classification purposes. Results from our pan-cancer discovery cohort revealed that AML was the only cancer type for which there is direct evidence for tumor-derived cfRNA in plasma in the form of *PML::RARA* fusion transcripts. Also, deconvolution of AML plasma cfRNA revealed a high fraction of myeloid progenitor cells, providing additional – albeit indirect – evidence for tumor-derived cfRNA. For solid tumor types, we identified differentially abundant mRNAs in plasma for every cancer versus control comparison, but a cancer type-specific signal was only observed in plasma from liver cancer patients through the enrichment of liver-specific gene sets. Liver is a major contributor to the plasma transcriptome[4] and its high vascularization and blood flow may facilitate mRNA release in blood upon liver cancer progression. Increased cfDNA contributions from the liver have also been observed in liver cancer patients[15]. Note that, despite the enrichment of liver-related mRNAs, the total cfRNA concentration was not increased in plasma from liver cancer patients, indicating that this signal was still strongly diluted.

Considering the organ contribution and dilution argument, other types of liquid biopsies may be better suited to monitor tumor-derived cfRNA for other cancer types. For instance, we could not detect enrichment of prostate tissue-related nor prostate cancer-specific transcripts in blood plasma from prostate cancer patients, in contrast to earlier findings in seminal plasma samples[16].

We did observe several general trends in patients' blood plasma transcriptomes in the pan-cancer cohort, which were confirmed in an independent cohort. The lower abundance of immune-related mRNAs may be linked to the suppressed immune system status in cancer patients. It was recently shown that local tumors can have a systemic impact on the immune system, and that different tumor sites of origin resulted in distinct relative abundances and activity profiles of immune cell types[17]. This may be linked to the observed variations in immune-related mRNA abundance, both between and within cancer types. The (immune) cell-related mRNA contributions agreed with reported cell abundance trends found in blood from several cancer patients[18], with the exception of neutrophil-related mRNAs that are lower abundant in plasma. However, neutrophils can have a dual role in cancer[19] and reduced neutrophil cell-free mRNA abundance may result from neutrophils specifically recruited to

tumor sites. Finally, the negative enrichment of blood/erythrocyte gene sets may be linked to

anemia, a common condition in cancer patients. Among the processes that we found

positively enriched in cancer patient plasma, some are linked to hallmarks for cancer

progression and metastasis, including epithelial-to-mesenchymal transition and increased

blood vessel signal that stem from leaky vasculature and angiogenesis[20].

A limitation of the pan-cancer cohort is that control samples were not always perfectly age

and sex-matched. The anaplastic astrocytoma, cervical cancer, and testicular germ cell tumor

patients were younger as these types predominantly appear at younger age. A dedicated

cohort with matched control samples may be better for revealing cancer-related changes in

these cancer types. Similarly, while male and female donors were balanced in the control

group, this was not always the case for some cancer types due to sex-specificity (e.g. prostate,

testicular, breast, cervical, and ovarian cancer) or sample availability. Nevertheless, at most 4

out of 8 donors were not sex-matched in cancer vs control group comparisons in the pan-

cancer cohort, and our main conclusions were not impacted when only using controls of the

same sex in the three-cancer cohort. Another limitation is the relatively small sample size per

cancer type, which might contribute to false positive results or insufficient power to detect

true differences.

The variable mRNA abundance in plasma, combined with the limited overlap of differentially

abundant mRNAs across cohorts of the same cancer type prompted an alternative approach

that can effectively deal with patient heterogeneity. The tail gene concept satisfies this

requirement by identifying mRNAs whose abundance in individual samples significantly

deviates from the abundance distribution in a reference group. While the dark channel

biomarker gene concept[4] is in part based on a more patient-centric approach, it also requires

differential abundance at group level to be considered as potential biomarkers. Moreover,

the dark channel concept looks explicitly at genes that are absent (dark) in control samples

and therefore cannot capture changes in transcript abundance of genes that are also present

in healthy plasma transcriptomes. Of note, 19 dark channel biomarker genes were identified

for lung and breast cancer by Larson et al.[4] but five of those genes could be readily detected

in control samples from our cohorts, indicating that the "darkness" (i.e. absence of gene

transcripts in control samples) should be re-evaluated in different cohorts.

Tail gene counts are a simple metric for classifying a biofluid sample as originating from a

cancer patient or control. Considering that it is not based on gene signatures with weighted

contributions of individual features, we propose it is more robust and compatible with

observed patient heterogeneity. Nevertheless, it requires a large and representative group of

cancer-free control samples. A control group only needs to be established once, if the entire

workflow – from sample collection to RNA-sequencing – is standardized across cancer and

control samples. This approach should minimize the introduction of batch effects that may

skew cfRNA distributions between a pre-established cohort of cancer-free controls and newly

profiled cancer or control samples. In this regard, our lab has demonstrated that preanalytical

variables (blood collection tube, time between blood collection and plasma preparation, RNA

extraction kit) can indeed dramatically impact cfRNA profiles[21].

Deviations in the number of tail genes are not necessarily restricted to cancer patients, nor

to blood plasma. Indeed, cfRNA from urine provides a good source of biomarker tail genes to

identify bladder cancer patients. Some of the identified biomarker tail genes have previously

been linked to cancer, with examples provided in Supplementary Analysis 3. Notably, other

diseases may also be characterized by an increase in tail genes, though the specific

(biomarker) tail genes may differ.

Given the limited sample sizes, we likely did not capture all variability in the current tail gene

sets, nor did we identify all possible tail genes. Follow-up studies with larger cohorts are

recommended to establish robust gene sets. Also, the applicability and overlap of tail genes

in non-malignant disease cohorts needs to be examined further. Similarly, while we have

preliminary evidence that biomarker tail genes are also significantly more numerous in low

stage cancer patients, additional follow-up studies comprising different stages across various

cancer types could reveal whether the concept is suited for early-stage cancer screening or

monitoring.

Methods

Sample cohorts

The study was approved by the ethics committee of Ghent University Hospital, Belgium (no.

B670201734362) and performed in accordance with the Declaration of Helsinki.

Pan-cancer plasma and three-cancer cohort

Blood plasma samples of 266 human donors were obtained from Proteogenex (CA, USA) with

informed consent from all donors. The pan-cancer discovery cohort covers 25 different cancer

types and a cancer-free control group. For each type, plasma was collected from 8 different

donors. The three-cancer cohort consisted of prostate cancer (PRAD), ovarian cancer (OV),

and endometrial cancer (UCEC) plasma samples, with 12 donors per type. This cohort also

included plasma samples from the 8 control donors of the pan-cancer cohort as well as from

22 additional control donors. The control donors in both cohorts where volunteers without

(diagnosed) malignant disease. For independently checking reproducibility of pan-cancer

results, only the control samples from the additional control donors were used. For tail gene

discovery, all control samples in the three-cancer cohort were used.

All cancer patients in both cohorts had locally advanced (stage 3) to metastatic cancer (stage

4), except for 6 seminoma patients (stage 1). Blood was drawn before treatment with 6

exceptions: 4 glioblastoma patients (grade 4-5) already received chemo and radiation

therapy, one prostate cancer patient with metastasis received hormone therapy, and one

melanoma patient with metastasis received immunotherapy. Demographic and clinical

information can be found in Supplementary Table 1.

<u>Lymphoma cohort</u>

The lymphoma cohort consisted of plasma samples from 65 human donors: 30 DLBCL

patients, 13 PMBCL patients, and 22 control donors. The control donors were volunteers

without (diagnosed) malignant disease and without indications of abnormalities in routine

blood analyses in the clinical lab. Plasma samples were collected following approval by the

ethics committee of Ghent University Hospital, Belgium (B670201733701), and written,

informed consent was obtained from all patients.

<u>Bladder cancer cohort</u>

The bladder cancer cohort is described in more detail elsewhere[14]. This cohort consists of

urine samples from 12 muscle-invasive bladder cancer patients and 12 control donors.

Blood collection and plasma preparation

Blood from the pan-cancer and three-cancer cohort donors was collected in EDTA vacutainer

tubes (Becton Dickinson, 367525). Blood was stored at 4 °C until plasma preparation which

started by gently inverting the EDTA tube 10 times and centrifugating for 10 min at 1500 g

(without brake at 4 °C). Supernatans was then transferred to 15 mL centrifuge tubes and

centrifuged again for 10 min at 1500 g (without brake at 4 °C). The resulting platelet depleted

plasma was transferred to 2 mL cryovials, frozen and stored at -80 °C within 4 hours of blood

collection. All plasma preparations were done in the same lab. Plasma samples were then

shipped on dry ice and only thawed on ice immediately before RNA isolation.

For the lymphoma cohort, 2.5 mL of blood was collected from each donor in PAXgene Blood DNA Tubes (BD Biosciences, 761165). Plasma was prepared in one lab by a one-step 15 min centrifugation at 1900 g without brake (room temperature) and stored at -80 °C within 4 hours of blood collection.

RNA isolation and gDNA removal

RNA isolation and subsequent library preparation was done by one lab technician per cohort. RNA was isolated from 200 µL of plasma with the miRNeasy Serum/Plasma kit (Qiagen, 217184), according to the manufacturer's instructions. For the pan-cancer and three-cancer cohort, 2 µL Sequin spike-in controls (1/1,300,000 of stock solutions mix A, Garvan Institute of Medical Research, Australia) was added to the lysate during RNA isolation as previously described[22]. For the lymphoma cohort, 2 µL of Sequin spike-in controls were added to the sample lysates (1/5000 of stock solution mix A (Garvan Institute of Medical Research) and 2 µL of External RNA Control Consortium (ERCC) spike-in controls (ThermoFisher Scientific, 4456740) were added to 12 µl RNA eluate.

Genomic DNA was removed by adding 1 µL HL-dsDNase (ArcticZymes, 70800-202) and 1.6 µL reaction buffer (ArcticZymes, 66001) to 12 µL RNA eluate, 10 min incubation at 37 °C, followed by 5 min incubation at 55 °C. RNA was stored at -80 °C and thawed on ice immediately before library preparation.

Messenger RNA capture library preparation, sequencing, and quantification

MRNA capture library preparation in pan-cancer and three-cancer cohorts started from 8.5 µL DNase treated RNA eluate. cDNA synthesis was performed using TruSeq RNA Library Prep for Enrichment (Illumina, 20020189) as previously described[22]. Briefly, RNA was fragmented, and first strand cDNA was generated using random priming. RNA templates were subsequently removed and replaced by a newly synthesized second strand of cDNA. AMPure XP beads (Beckman Coulter Life Sciences, A63881) were used for purifying the blunt-ended double stranded cDNA. 30 µL cDNA of each sample was then used as input for Illumina DNA Prep with Enrichment (previously Nextera Flex for Enrichment; Illumina, 20025524). Tagmentation and amplification steps were done according to manufacturer's instructions. Quality of resulting pre-enriched libraries was assessed using a high sensitivity Small DNA Fragment Analysis Kit (Agilent Technologies, DNF-477-0500). The libraries were randomly pooled per 8 or 6 samples, for the pan-cancer and three-cancer cohort, respectively, based

on their relative concentrations determined using qPCR for reference genes YWHAZ, ACTB,

B2M, and UBC. Each multiplex pool was concentrated to a volume of 15 µL with AMPure XP

beads (Beckman Coulter Life Sciences, A63881). Finally, enrichment was performed using

probes from the Illumina Exome Panel (Illumina, 20020183), probes complementary to the

spike-in controls, and blocking probes against globin (anti-CEX) as previously described[22]. At

the end of the enrichment workflow, equimolar library pools were prepared based on qPCR

quantification with KAPA Library Quantification Kit (Roche Diagnostics, KK4854).

Paired-end sequencing of both cohorts was performed (2x100 nucleotides) on a NovaSeq

6000. For the pan-cancer cohort, a NovaSeq S2 kit (Illumina, 20028315) was used with

standard workflow loading of 1.55 nM (1% PhiX). For the three-cancer cohort, a NovaSeq S1

kit (Illumina, 20028318) was used with Xp workflow loading of 1.25 nM (2% PhiX).

Adapter trimming and removal of reads shorter than 20 nucleotides was done with cutadapt

(v1.18). Read quality was assessed with FastQC (v0.11.9) and low-quality reads were filtered:

only reads where at least 80% of bases in both mates have a quality score ≥20 (99% accuracy)

were kept (between 87 and 99% of reads/sample). Samples with very few reads (< 2M) were

removed from all analyses. More specifically, 4 samples were removed in the pan-cancer

plasma cohort (1 lymphoma, 1 bladder, 1 head and neck, and 1 lung cancer sample) and 4

samples in the three-cancer cohort (3 control samples, of which 1 repeated from first cohort,

and 1 ovarian cancer) as indicated in Supplementary Table 1. Quality filtered reads were then

mapped with STAR[23] (v2.6.0) using the default parameters (except for --twopassMode Basic,

--outFilterMatchNmin 20 and --outSAMprimaryFlag AllBestScore). The reference files for all

analyses were based on genome build GRCh38 and transcriptome build Ensembl v91,

complemented with spike annotations. Finally, gene counts were determined with HTSeq[24]

(v0.11.0) in non-stranded mode, only considering uniquely mapping reads.

Total RNA library preparation, sequencing, and quantification

Total RNA sequencing libraries of the lymphoma cohort were prepared starting from 8 µL of

RNA eluate using the SMARTer Stranded Total RNA-Seq Kit v3 – Pico Input Mammalian

(Takara, 634487) according to the manufacturer's protocol. Equimolar library pools were

prepared based on qPCR quantification with KAPA Library Quantification Kit (Roche

Diagnostics, KK4854). The libraries were paired-end sequenced (2x100 nucleotides) on a

NovaSeq 6000 instrument using a NovaSeq S2 kit (Illumina, 20028315) with standard

workflow loading of 0.65 nM (2% PhiX).

After adapter trimming with cutadapt (v1.18) and quality control with FASTQC (v0.11.9),

reads were mapped with STAR[23] (v2.7.3) using default options and the GRCh38 reference

described above. Resulting BAM files were deduplicated using UMI-tools (v1.0.0) based on

the unique molecular identifier (UMI) sequences in the Pico v3 SMART UMI adapters. Gene

counts were determined with HTSeq[24] (v0.11.0) in reverse stranded mode, only considering

uniquely mapping reads.

DNA contamination check

To assess possible DNA contamination, we looked at splicing and exonic coverage. For each

cohort, the number of reads going to spliced junctions was determined using samtools

(v1.16.1) and regional coverage was determined using a combination of samtools (v1.16.1)

and bedtools (v2.30.0) with BED files containing intronic, intergenic and exonic regions. The

summary of splicing and regional coverage results can be found in Supplementary Table 8.

Data analyses

Most data processing and visualization was done in R (v4.2.1) using tidyverse (v1.3.2) and

pheatmap (v1.0.12). Other tools and R packages used for specific analyses are mentioned

below. Color schemes are based on Paul Tol's technical note[25].

<u>Detection threshold</u>

To remove noisy datapoints, we applied a threshold of at least 10 counts. This threshold was

based on the median threshold that removes at least 95% of single positive genes[26] - genes

that have counts in one replicate but not in the other - between control samples.

<u>Spike counts and mRNA concentration</u>

Spike counts and Spearman correlations are shown in Supplementary Analysis 3. MRNA

concentration was determined based on spikes as previously described[22]. Briefly, the mass of

a specific Sequin spike-in control was calculated based on the input concentration and volume

of spike-in mix added to the sample. The corresponding mRNA concentration was then

estimated by multiplying the spike mass by the ratio of reads mapped to the human genome

versus the number of reads mapped to the specific spike, and finally dividing the obtained

mass by the plasma volume of the sample. In this study, all Sequin spikes above detection

threshold were considered and the geometric mean per sample was taken as the sample's

mRNA concentration.

<u>Fusion gene detection</u>

FusionCatcher[27] (v1.30) was used with default settings for fusion transcript identification. Stringent filtering was applied to exclude potential false positives: transcripts with a FusionCatcher label indicative for false positives, transcripts with reads simultaneously mapping to both fusion partners, and transcripts with fusion partners less than 100 kbp apart were filtered out. Only exon-exon fusions were included and detected fusions in plasma were compared to fusions in the Fusion Gene annotation DataBase (FusionGDB)[28], focusing on fusion genes identified in tissue samples of The Cancer Genome Atlas[29].

708 Differential abundance and principal component analysis

709 DESeq2 (v1.36.0) was used for normalization and differential abundance analysis. MRNAs were pre-filtered by requiring gene counts equal to or greater than the detection threshold in at least half of the tumor or half of the control samples. In the DESeq2 result table, genes with a Benjamini-Hochberg corrected p-value (q) below 0.05 and an absolute $\log_2$ fold change above 1 were considered differentially abundant in cancer versus control (higher abundant: q < 0.05 and log2 fold change > 1; lower abundant: q < 0.05 and log2 fold change < -1). Principal component analysis was performed with DESeq2 plotPCA on the 500 most variable genes after applying variance stabilizing transformation. Volcano plots were visualized using EnhancedVolcano (v1.14.0) and area-proportional Euler diagrams were made using eulerr (v6.1.1). Differential abundance analysis results are freely available at Zenodo (doi:10.5281/zenodo.7953707).

720 Gene set enrichment and overrepresentation

721 Fgsea[30] (v1.22.0) was used for preranked gene set enrichment analysis based on $\log_2$ transformed fold changes between cancer and controls obtained from DESeq2 differential abundance analysis. Significant enrichment was defined by a false discovery rate ≤ 0.05. Hallmark[9] and Canonical Pathways gene sets derived from Kyoto Encyclopedia of Genes and Genomes (KEGG)[10], http://www.pathway.jp, were obtained via the Molecular Signatures Database, MSigDB (v2022.1)[31]. Besides these MSigDB gene sets, custom tissue and cell type specific gene sets were made using inhouse and external references as described below. Gene set enrichment analysis results and custom gene sets are available at Zenodo (doi:10.5281/zenodo.7953707). Functional analysis of mRNA sets was done using the functional annotation tool of DAVID (v2021)[32,33] and - for custom gene sets - the fora function of fgsea. For each functional analysis, a background was provided which included all mRNAs satisfying the count threshold in at least one sample.

RNA Atlas cell type gene sets

These cell type gene sets were defined based on total RNA sequencing data of cells and cell

lines in the RNA Atlas[34]. Protein coding gene inclusion criteria were an expression of at least

16 counts after variance stabilizing transformation and an expression fold change of at least

10 compared to the cell type with second highest expression. 32 different cell type sets were

defined, of which 15 had more than 5 genes, yet the largest gene set only included 10 genes.

Tabula Sapiens cell type gene sets

These cell type gene sets were based on the Tabula Sapiens v1 basis matrix defined by

Vorperian et al[2]. Protein coding genes with at least 5 CPM and an expression fold change of

at least 10 compared to the cell type with the second highest expression were retained. In

total, 39 gene sets were obtained, of which 13 sets had more than 5 genes. The largest gene

set contained 26 genes.

GTEX tissue gene sets

These tissue gene sets were defined using SPECS specificity scores[35] of GTEx v7[36] tissue

samples, summarized in https://specs.cmgg.be. Criteria for protein coding gene inclusion in a

certain tissue gene set were a SPECS score ≥ 0.98 and a median TPM ≥ 5. Large gene sets were

reduced to the top 200 genes based on the highest SPECS score. 23 out of 27 defined tissues

gene sets included more than 5 genes and the median gene set size was 50.

HPA tissue gene sets

These tissue gene sets were defined based on expression data from the Human Protein Atlas[37]

(HPA, v23, https://v23.proteinatlas.org/). Human Protein Atlas protein coding genes needed

to have a TPM value of at least 5 and expression that is at least 10 times higher in the tissue

with highest expression compared to the tissue with second highest expression. Finally, large

gene sets were reduced to the top 200 genes based on the highest fold changes. Gene sets

for 30 tissues were defined, with 21 gene sets including more than 5 genes and a median gene

set size of 8.

TCGA cancer tissue gene sets

These gene sets were defined similarly to the GTEX gene sets but using expression in The

Cancer Genome Atlas (TCGA) cancer tissue samples, generated by the TCGA Research

Network: https://www.cancer.gov/tcga. Protein coding genes with a SPECS score of at least

0.98 in a certain tissue were included in the gene set with a limit of 200 genes, based on

highest SPECS score. 23 cancer tissue gene sets were obtained with a median gene set size of

21 genes. 19 out of 23 gene sets included more than 5 genes.

<u>Cell type deconvolution</u>

NuSVR deconvolution using the Tabula Sapiens v1 basis matrix was performed as described

by Vorperian et al.[2] and the accompanying GitHub repository,

https://github.com/sevahn/deconvolution. As recommended by the authors, data was CPM

normalized and no log transformation was performed. Note that the erythrocyte fraction is

underestimated due to the absence of hemoglobin probes in mRNA capture sequencing.

<u>Tail genes</u>

To identify tail genes, transcript counts of every sample were first converted to a customized

z-score based on the mean and standard deviation in the reference group, including all control

samples except the sample of interest. More specifically, a pseudocount was added to all

normalized transcript counts followed by log_2 transformation. Then, for each gene, the mean

and standard deviation of these transformed counts in the reference group was used to scale

the transformed counts in the sample of interest.

Tail genes were then defined as genes with at least 40 counts after DESeq2 normalization and

deviating more than 3 standard deviations from the mean of the control reference ($|z| > 3$).

For each gene in a sample of interest:

782
$$z_{gene} = \frac{log_2\big(normalized\ counts_{gene} + 1\big) - \overline{ref}_{gene}}{SD_{ref_{gene}}}$$

where $\overline{ref}_{gene}$ and $SD_{ref_{gene}}$ are respectively the mean and standard deviation of log_2

transformed counts for this gene over all (other) control samples.

Fisher's exact tests (based on tail gene characteristics ($|z| > 3$ and normalized counts ≥ 40)

and donor cancer/control status) were used to select a subset of tail genes, named biomarker

tail genes (BTG), that are specifically associated to the disease state.

Binary logistic regression, R glm function with binomial family, was used to classify a sample

as cancer or control based on the number of biomarker tail genes. 10x 5-fold cross-validation

was used: each time 80% of data (stratified partitioning) was used for BTG identification and

model training, the remaining 20% was used to test the classification performance with that

particular BTG set. Note that the reference used for z-score calculation never included

controls from the test set. For sex-specific cancer types, only samples from control donors

with the same sex were used for training and testing. Based on these predictions, the Receiver

Operating Characteristic (ROC) curve and Area Under Curve (AUC) were calculated and the

mean was visualized using pROC (v1.18.0)[38].

Cross-validation resulted in different BTG sets. Consensus BTG were defined as BTG identified

in at least half of the cross-validation iterations (≥25 out of 50). The number of tail genes per

sample that belong to this consensus set was visualized, where the z-scores were again based

on the reference with all controls from the same cohort, except the sample itself.

For internal verification, all sample labels were randomly reshuffled using the sample function

in R without replacement. Next, tail gene identification and evaluation were done based on

the new class labels (using the new control samples as reference). This process was repeated

20 times. For 10 iterations of label swapping, we also did biomarker tail gene identification

and evaluation with 10x 5-fold cross-validation.

Statistics

Kruskal-Wallis tests were used to compare multiple groups, and Wilcoxon rank-sum tests

were used to compare two groups. Corresponding statistical significance, effect sizes and

confidence intervals were calculated with rstatix (v0.7.2). For individual testing, p-values

smaller than 0.05 were considered significant. In case of multiple testing, the Benjamini-

Hochberg procedure was used to calculate false discovery rate adjusted p-values (q-values)

and significance was defined as q smaller than 0.05.

Significance of overlap between gene sets was determined by Fisher's exact test in

GeneOverlap v1.32.0. The universe consisted of all genes considered for the corresponding

differential abundance or tail gene analyses (see filtering above). A Jaccard index was

calculated to assess similarity between the gene sets, with 0 indicating no similarity and 1

indicating identical sets. Jonckheere-Terpstra test was used to assess whether there was a

significant trend between the cancer stage and the number of biomarker tail genes in cancer

samples.

Data availability

Raw RNA-sequencing data is available under restricted access in the European Genome-

phenome Archive (EGA) to preserve individuals' privacy and comply with patient consent for

data sharing under the European General Data Protection Regulation. The pan-cancer and

three-cancer cohort FASTQs can be found under study EGAS00001006755 (dataset

Code availability

Acknowledgements

Figures 1a and 5b were created with BioRender.com. We would like to thank Tim Mercer for providing the Sequin spikes, Eva Hulstaert and Francisco Avila Cobos for their support during the first phase of the project, and Anneleen Decock for her feedback on the initial draft. We would also like to thank the Biostatistics Unit of the Faculty of Medicine and Health Sciences (Ghent University) for their feedback on the tail gene performance assessment.

Funding

This work was supported by Ghent University (BOF; BOF19/DOC/228), Ghent University Hospital, Fund for Scientific Research Flanders (FWO; 11C1623N to A.M., 11H7523N to P.D., G0B2820N), and Kom Op Tegen Kanker (Stand up to Cancer, the Flemish cancer society).

Conflict of interest

A.M., J.V. and P.M. are inventors on a patent application regarding the tail gene concept (WO2024200811A1).

References

1. Pessoa, L. S., Heringer, M. & Ferrer, V. P. ctDNA as a cancer biomarker: A broad overview. *Critical Reviews in Oncology/Hematology* **155**, 103109 (2020).

2. Vorperian, S. K., Moufarrej, M. N. & Quake, S. R. Cell types of origin of the cell-free transcriptome. *Nat Biotechnol* **40**, 855–861 (2022).

3. Moufarrej, M. N. *et al.* Early prediction of preeclampsia in pregnancy with cell-free RNA.
Nature **602**, 689–694 (2022).

4. Larson, M. H. *et al.* A comprehensive characterization of the cell-free transcriptome
reveals tissue- and subtype-specific biomarkers for cancer detection. *Nat Commun* **12**,
2357 (2021).

5. Chen, S. *et al.* Cancer type classification using plasma cell-free RNAs derived from human
and microbes. *eLife* **11**, e75181 (2022).

6. Roskams-Hieter, B. *et al.* Plasma cell-free RNA profiling distinguishes cancers from pre-
malignant conditions in solid and hematologic malignancies. *npj Precis. Onc.* **6**, 1–11
(2022).

7. Bryzgunova, O. E., Konoshenko, M. Y. & Laktionov, P. P. Concentration of cell-free DNA in
different tumor types. *Expert Review of Molecular Diagnostics* **21**, 63–75 (2021).

8. Liquori, A. *et al.* Acute Promyelocytic Leukemia: A Constellation of Molecular Events
around a Single PML-RARA Fusion Gene. *Cancers (Basel)* **12**, 624 (2020).

9. Liberzon, A. *et al.* The Molecular Signatures Database (MSigDB) hallmark gene set
collection. *Cell Syst* **1**, 417–425 (2015).

10. Kanehisa, M. & Goto, S. KEGG: Kyoto Encyclopedia of Genes and Genomes. *Nucleic Acids
Research* **28**, 27–30 (2000).

11. Khwaja, A. *et al.* Acute myeloid leukaemia. *Nat Rev Dis Primers* **2**, 1–22 (2016).

12. Giannakeas, V. *et al.* Analysis of Platelet Count and New Cancer Diagnosis Over a 10-Year
Period. *JAMA Network Open* **5**, e2141633 (2022).

13. Haemmerle, M., Stone, R. L., Menter, D. G., Afshar-Kharghan, V. & Sood, A. K. The Platelet
Lifeline to Cancer: Challenges and Opportunities. *Cancer Cell* **33**, 965–983 (2018).

14. Hulstaert, E. *et al.* Charting Extracellular Transcriptomes in The Human Biofluid RNA Atlas.
Cell Reports **33**, 108552 (2020).

15. Sun, K. *et al.* Plasma DNA tissue mapping by genome-wide methylation sequencing for
noninvasive prenatal, cancer, and transplantation assessments. *Proceedings of the
National Academy of Sciences* **112**, E5503–E5512 (2015).

16. Hulstaert, E. *et al.* Exploring the extracellular transcriptome in seminal plasma for non-
invasive   prostate   cancer   diagnosis.   2021.05.11.21256306   Preprint   at
https://doi.org/10.1101/2021.05.11.21256306 (2021).

17. Allen, B. M. *et al.* Systemic dysfunction and plasticity of the immune macroenvironment
in cancer models. *Nat Med* **26**, 1125–1134 (2020).

18. Hiam-Galvez, K. J., Allen, B. M. & Spitzer, M. H. Systemic immunity in cancer. *Nat Rev*
Cancer **21**, 345–359 (2021).

19. Xiong, S., Dong, L. & Cheng, L. Neutrophils in cancer carcinogenesis and metastasis.
Journal of Hematology & Oncology **14**, 173 (2021).

20. Lugano, R., Ramachandran, M. & Dimberg, A. Tumor angiogenesis: causes, consequences,
challenges and opportunities. *Cell. Mol. Life Sci.* **77**, 1745–1770 (2020).

21. exRNAQC Consortium *et al.* Blood collection tube and RNA purification method
recommendations for extracellular RNA transcriptome profiling: A large-scale pre-
analytical variable performance evaluation. Preprint at https://doi.org/10.21203/rs.3.rs-
2409038/v2 (2024).

22. Hulstaert, E. *et al.* Messenger RNA capture sequencing of extracellular RNA from human
biofluids using a comprehensive set of spike-in controls. *STAR Protocols* **2**, 100475 (2021).

23. Dobin, A. *et al.* STAR: ultrafast universal RNA-seq aligner. *Bioinformatics* **29**, 15–21 (2013).

24. Anders, S., Pyl, P. T. & Huber, W. HTSeq—a Python framework to work with high-
throughput sequencing data. *Bioinformatics* **31**, 166–169 (2015).

25. Tol, P. Colour Schemes, Technical Note SRON/EPS/TN/09-002. (2012).

26. Mestdagh, P. *et al.* Evaluation of quantitative miRNA expression platforms in the
microRNA quality control (miRQC) study. *Nature Methods* **11**, 809–815 (2014).

27. Nicorici, D. *et al.* FusionCatcher – a tool for finding somatic fusion genes in paired-end
RNA-sequencing data. 011650 Preprint at https://doi.org/10.1101/011650 (2014).

28. Kim, P. & Zhou, X. FusionGDB: fusion gene annotation DataBase. *Nucleic Acids Research*
47, D994–D1004 (2019).

29. Gao, Q. *et al.* Driver Fusions and Their Implications in the Development and Treatment of
Human Cancers. *Cell Reports* **23**, 227-238.e3 (2018).

30. Korotkevich, G. *et al.* Fast gene set enrichment analysis. 060012 Preprint at
https://doi.org/10.1101/060012 (2021).

31. Subramanian, A. *et al.* Gene set enrichment analysis: A knowledge-based approach for
interpreting genome-wide expression profiles. *Proceedings of the National Academy of*
Sciences **102**, 15545–15550 (2005).

32. Huang, D. W., Sherman, B. T. & Lempicki, R. A. Systematic and integrative analysis of large
gene lists using DAVID bioinformatics resources. *Nat Protoc* **4**, 44–57 (2009).

33. Sherman, B. T. *et al.* DAVID: a web server for functional enrichment analysis and
functional annotation of gene lists (2021 update). *Nucleic Acids Res* **50**, W216–W221
(2022).

34. Lorenzi, L. *et al.* The RNA Atlas expands the catalog of human non-coding RNAs. *Nat
Biotechnol* **39**, 1453–1465 (2021).

35. Everaert, C., Volders, P.-J., Morlion, A., Thas, O. & Mestdagh, P. SPECS: a non-parametric
method to identify tissue-specific molecular features for unbalanced sample groups. *BMC
Bioinformatics* **21**, 58 (2020).

36. Lonsdale, J. *et al.* The Genotype-Tissue Expression (GTEx) project. *Nat Genet* **45**, 580–585
(2013).

37. Uhlén, M. *et al.* Tissue-based map of the human proteome. *Science* **347**, 1260419 (2015).

38. Robin, X. *et al.* pROC: an open-source package for R and S+ to analyze and compare ROC
curves. *BMC Bioinformatics* **12**, 77 (2011).

929